IBDEI1XO ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30884,1,4,0)
;;=4^N01.9
;;^UTILITY(U,$J,358.3,30884,2)
;;=^5015510
;;^UTILITY(U,$J,358.3,30885,0)
;;=N02.0^^123^1597^79
;;^UTILITY(U,$J,358.3,30885,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30885,1,3,0)
;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
;;^UTILITY(U,$J,358.3,30885,1,4,0)
;;=4^N02.0
;;^UTILITY(U,$J,358.3,30885,2)
;;=^5015511
;;^UTILITY(U,$J,358.3,30886,0)
;;=N02.1^^123^1597^78
;;^UTILITY(U,$J,358.3,30886,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30886,1,3,0)
;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
;;^UTILITY(U,$J,358.3,30886,1,4,0)
;;=4^N02.1
;;^UTILITY(U,$J,358.3,30886,2)
;;=^5015512
;;^UTILITY(U,$J,358.3,30887,0)
;;=N02.2^^123^1597^76
;;^UTILITY(U,$J,358.3,30887,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30887,1,3,0)
;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
;;^UTILITY(U,$J,358.3,30887,1,4,0)
;;=4^N02.2
;;^UTILITY(U,$J,358.3,30887,2)
;;=^5015513
;;^UTILITY(U,$J,358.3,30888,0)
;;=N02.3^^123^1597^73
;;^UTILITY(U,$J,358.3,30888,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30888,1,3,0)
;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,30888,1,4,0)
;;=4^N02.3
;;^UTILITY(U,$J,358.3,30888,2)
;;=^5015514
;;^UTILITY(U,$J,358.3,30889,0)
;;=N02.4^^123^1597^72
;;^UTILITY(U,$J,358.3,30889,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30889,1,3,0)
;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30889,1,4,0)
;;=4^N02.4
;;^UTILITY(U,$J,358.3,30889,2)
;;=^5015515
;;^UTILITY(U,$J,358.3,30890,0)
;;=N02.5^^123^1597^77
;;^UTILITY(U,$J,358.3,30890,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30890,1,3,0)
;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,30890,1,4,0)
;;=4^N02.5
;;^UTILITY(U,$J,358.3,30890,2)
;;=^5015516
;;^UTILITY(U,$J,358.3,30891,0)
;;=N02.6^^123^1597^74
;;^UTILITY(U,$J,358.3,30891,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30891,1,3,0)
;;=3^Recurrent & perst hematur w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30891,1,4,0)
;;=4^N02.6
;;^UTILITY(U,$J,358.3,30891,2)
;;=^5015517
;;^UTILITY(U,$J,358.3,30892,0)
;;=N02.7^^123^1597^75
;;^UTILITY(U,$J,358.3,30892,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30892,1,3,0)
;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,30892,1,4,0)
;;=4^N02.7
;;^UTILITY(U,$J,358.3,30892,2)
;;=^5015518
;;^UTILITY(U,$J,358.3,30893,0)
;;=N02.8^^123^1597^80
;;^UTILITY(U,$J,358.3,30893,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30893,1,3,0)
;;=3^Recurrent & perst hematur w/ oth morphologic changes
;;^UTILITY(U,$J,358.3,30893,1,4,0)
;;=4^N02.8
;;^UTILITY(U,$J,358.3,30893,2)
;;=^5015519
;;^UTILITY(U,$J,358.3,30894,0)
;;=N02.9^^123^1597^81
;;^UTILITY(U,$J,358.3,30894,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30894,1,3,0)
;;=3^Recurrent & perst hematur w/ unsp morphologic changes
;;^UTILITY(U,$J,358.3,30894,1,4,0)
;;=4^N02.9
;;^UTILITY(U,$J,358.3,30894,2)
;;=^5015520
;;^UTILITY(U,$J,358.3,30895,0)
;;=N03.0^^123^1597^18
;;^UTILITY(U,$J,358.3,30895,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30895,1,3,0)
;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,30895,1,4,0)
;;=4^N03.0
;;^UTILITY(U,$J,358.3,30895,2)
;;=^5015521
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XO 3749 printed Oct 16, 2024@18:18:37 Page 2
IBDEI1XO ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30884,1,4,0)
+2 ;;=4^N01.9
+3 ;;^UTILITY(U,$J,358.3,30884,2)
+4 ;;=^5015510
+5 ;;^UTILITY(U,$J,358.3,30885,0)
+6 ;;=N02.0^^123^1597^79
+7 ;;^UTILITY(U,$J,358.3,30885,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,30885,1,3,0)
+10 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
+11 ;;^UTILITY(U,$J,358.3,30885,1,4,0)
+12 ;;=4^N02.0
+13 ;;^UTILITY(U,$J,358.3,30885,2)
+14 ;;=^5015511
+15 ;;^UTILITY(U,$J,358.3,30886,0)
+16 ;;=N02.1^^123^1597^78
+17 ;;^UTILITY(U,$J,358.3,30886,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,30886,1,3,0)
+20 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
+21 ;;^UTILITY(U,$J,358.3,30886,1,4,0)
+22 ;;=4^N02.1
+23 ;;^UTILITY(U,$J,358.3,30886,2)
+24 ;;=^5015512
+25 ;;^UTILITY(U,$J,358.3,30887,0)
+26 ;;=N02.2^^123^1597^76
+27 ;;^UTILITY(U,$J,358.3,30887,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,30887,1,3,0)
+30 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
+31 ;;^UTILITY(U,$J,358.3,30887,1,4,0)
+32 ;;=4^N02.2
+33 ;;^UTILITY(U,$J,358.3,30887,2)
+34 ;;=^5015513
+35 ;;^UTILITY(U,$J,358.3,30888,0)
+36 ;;=N02.3^^123^1597^73
+37 ;;^UTILITY(U,$J,358.3,30888,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,30888,1,3,0)
+40 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
+41 ;;^UTILITY(U,$J,358.3,30888,1,4,0)
+42 ;;=4^N02.3
+43 ;;^UTILITY(U,$J,358.3,30888,2)
+44 ;;=^5015514
+45 ;;^UTILITY(U,$J,358.3,30889,0)
+46 ;;=N02.4^^123^1597^72
+47 ;;^UTILITY(U,$J,358.3,30889,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,30889,1,3,0)
+50 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
+51 ;;^UTILITY(U,$J,358.3,30889,1,4,0)
+52 ;;=4^N02.4
+53 ;;^UTILITY(U,$J,358.3,30889,2)
+54 ;;=^5015515
+55 ;;^UTILITY(U,$J,358.3,30890,0)
+56 ;;=N02.5^^123^1597^77
+57 ;;^UTILITY(U,$J,358.3,30890,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,30890,1,3,0)
+60 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
+61 ;;^UTILITY(U,$J,358.3,30890,1,4,0)
+62 ;;=4^N02.5
+63 ;;^UTILITY(U,$J,358.3,30890,2)
+64 ;;=^5015516
+65 ;;^UTILITY(U,$J,358.3,30891,0)
+66 ;;=N02.6^^123^1597^74
+67 ;;^UTILITY(U,$J,358.3,30891,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,30891,1,3,0)
+70 ;;=3^Recurrent & perst hematur w/ dense deposit disease
+71 ;;^UTILITY(U,$J,358.3,30891,1,4,0)
+72 ;;=4^N02.6
+73 ;;^UTILITY(U,$J,358.3,30891,2)
+74 ;;=^5015517
+75 ;;^UTILITY(U,$J,358.3,30892,0)
+76 ;;=N02.7^^123^1597^75
+77 ;;^UTILITY(U,$J,358.3,30892,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,30892,1,3,0)
+80 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
+81 ;;^UTILITY(U,$J,358.3,30892,1,4,0)
+82 ;;=4^N02.7
+83 ;;^UTILITY(U,$J,358.3,30892,2)
+84 ;;=^5015518
+85 ;;^UTILITY(U,$J,358.3,30893,0)
+86 ;;=N02.8^^123^1597^80
+87 ;;^UTILITY(U,$J,358.3,30893,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,30893,1,3,0)
+90 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
+91 ;;^UTILITY(U,$J,358.3,30893,1,4,0)
+92 ;;=4^N02.8
+93 ;;^UTILITY(U,$J,358.3,30893,2)
+94 ;;=^5015519
+95 ;;^UTILITY(U,$J,358.3,30894,0)
+96 ;;=N02.9^^123^1597^81
+97 ;;^UTILITY(U,$J,358.3,30894,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,30894,1,3,0)
+100 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
+101 ;;^UTILITY(U,$J,358.3,30894,1,4,0)
+102 ;;=4^N02.9
+103 ;;^UTILITY(U,$J,358.3,30894,2)
+104 ;;=^5015520
+105 ;;^UTILITY(U,$J,358.3,30895,0)
+106 ;;=N03.0^^123^1597^18
+107 ;;^UTILITY(U,$J,358.3,30895,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,30895,1,3,0)
+110 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
+111 ;;^UTILITY(U,$J,358.3,30895,1,4,0)
+112 ;;=4^N03.0
+113 ;;^UTILITY(U,$J,358.3,30895,2)
+114 ;;=^5015521
